Research programme: immuno-microbials - Evelo Biosciences

Drug Profile

Research programme: immuno-microbials - Evelo Biosciences

Alternative Names: Immuno-microbial therapeutics - Evelo Biosciences; Monoclonal microbial therapeutics - Evelo Biosciences

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Epiva Biosciences
  • Developer Evelo Biosciences
  • Class Anti-inflammatories; Bacteria; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 16 Nov 2017 Evelo Biosciences in-licenses technology and patent estate from Mayo Clinic
  • 16 Nov 2017 Evelo Biosciences has patent protection for monoclonal microbials
  • 11 Jul 2017 Evelo Biosciences plans clinical trials in Autoimmune disorders and Inflammation in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top